Work

Figure 2 from Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Year: 2025

Type: other

Abstract: Best percentage change from baseline in target lesions per RECIST version 1.1 in (A) arm 1 (IT MK-2118 monotherapy), (B) arm 2 (IT MK-2118 plus IV pembrolizumab), and (C) arm 4 (SC MK-2118 plus IV pembrolizumab).

DOI: 10.1158/1078-0432.28703790

Authors: Jason J. Luke, Randy F. Sweis, J. Randolph Hecht, Reva Schneider, Mark N. Stein, Talia Golan, Timothy A. Yap, Anuradha Khilnani, Mo Huang, Runchen Zhao, Thomas Jemielita, Sandip Pravin Patel

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4409038999

Cites:

Cited by:

Related to: 10